<DOC>
	<DOCNO>NCT01241760</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness telaprevir administer twice daily versus every 8 hour combination Peg-IFN-alfa-2a ribavirin treatment-naïve participant chronic HCV genotype 1 infection .</brief_summary>
	<brief_title>VX-950-C211 - A Dosing Regimen Study ( Twice Daily Versus Every 8 Hours ) Telaprevir Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( person know study drug assignment ) multicenter study evaluate effectiveness telaprevir administer orally 1125 milligram ( mg ) twice daily versus 750mg every 8 hour combination Peg-IFN-alfa-2a , administer via intramuscular injection week , ribavirin , administer oral tablet twice day , treatment-naïve study participant chronic hepatitis C virus ( HCV ) genotype 1 infection . Telaprevir give orally ( mouth ) Day 1 Week 12 3 tablet ( 1125mg ) twice daily 2 tablet ( 750mg ) every 8 hour . Peg-IFN-alfa-2a administer week injection skin ( 180 microgram/week ) Day 1 Week 24 48 ( base patient 's treatment response week 4 ) . Ribavirin administer orally ( mouth ) twice daily Day 1 Week 24 48 ( base participant 's treatment response week 4 ) 1,000-1,200 mg per day . After end treatment ( Week 24 , Week 48 , early discontinuation study drug ) , participant undetectable HCV RNA end treatment require attend follow-up visit Week 72 safety/tolerability assessment perform throughout treatment period follow-up period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patient chronic HCV infection genotype 1 HCV RNA level &gt; 1,000 IU/mL Patients previous treatment hepatitis C Patient must documentation liver biopsy within 2 year screen visit patient must agree biopsy perform within screen period Patients cirrhosis serum alphafetoprotein ( AFP ) &lt; = 50 ng/mL . If AFP &gt; 50 ng/mL , absence mass must demonstrate ultrasound within screen period A female patient childbearing potential nonvasectomized male patient female partner childbearing potential must agree use 2 effective method birth control screen 6 month ( female patient ) 7 month ( male patient ) last dose RBV . Patient infect coinfected HCV another genotype genotype 1 and/or patient infect one genotype subtype Patient preexist psychiatric condition Patient history decompensated liver disease show evidence significant liver disease addition hepatitis C Patient human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) coinfection Patient active malignant disease history malignant disease within past 5 year ( exception treat basal cell carcinoma ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Genotype 1 chronic hepatitis C</keyword>
	<keyword>VX-950-C211</keyword>
	<keyword>VX-950</keyword>
	<keyword>IL28B</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>BID</keyword>
	<keyword>Q8h</keyword>
	<keyword>SOC</keyword>
</DOC>